Need help finding what you are looking for?
Contact Us
PUBLISHER: Roots Analysis | PRODUCT CODE: 1439184
PUBLISHER: Roots Analysis | PRODUCT CODE: 1439184
Oncology Precision Medicine Market: Industry Trends & Global Forecasts, Till 2035: Distribution by Type of Cancer Targeted, Route of Administration, Type of Molecule, Drug Class, Key Geographical Regions, Leading Drug Developers & Sales Forecast
PUBLISHED:
PAGES: 468 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Oncology Precision Medicine Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Cancer Targeted (Bladder Cancer, Blood / Hematologic Cancer, Breast Cancer, Cervical Cancer, Gastrointestinal Cancer, Head and Neck Squamous Cell Cancer, Lung Cancer, Skin Cancer and Others), Route of Administration (Oral, Intravenous and Others), Type of Molecule (Small Molecules and Biologics), Drug Class (Kinase Inhibitors, Enzyme Inhibitors, Immune Checkpoint Inhibitors and Others), Key Geographical Regions (North America (US, Canada), Europe (France, Germany, Italy, Spain and UK), Asia (China, Japan, Korea and India), Middle East and North Africa (UAE, Israel, Qatar, Rest of Middle East and North Africa) and Latin America (Brazil, Argentina, Chile and Rest of Latin America), Leading Drug Developers and Sales Forecast
The oncology precision medicine market is valued at USD 130 billion in 2023 growing at a CAGR of 8.93% during the forecast period 2023-2035.
Cancer is globally acknowledged as one of the most lethal diseases, characterized by its widespread occurrence and high mortality rates. As per data from the World Health Organization, in 2020 alone, there were approximately 20 million new cases of cancer and 10 million cancer-related deaths reported annually, with projections indicating a staggering 60% increase in these figures by the year 2040. The rise in cancer prevalence and pathogenesis is attributed to various factors including alcohol consumption, obesity, viral infections, exposure to radiation and chemicals. Traditional treatment methods for cancer, such as surgery, radiation therapy, and chemotherapy, are commonly employed. Additionally, there are complementary or alternative therapeutic approaches like hormone therapy, immunotherapy, and nanotherapy. However, these treatments have shown limitations in addressing the intrinsic genetic abnormalities underlying cancer, which can stem from specific mutations in oncogenes, tumor suppressor genes, and DNA repair genes. To overcome the limitations of existing treatments, the concept of precision medicine, also known as personalized medicine, has emerged. Precision medicine utilizes genomic information to develop targeted therapies tailored to individual patients. By analyzing tumor characteristics, genetic data, patient lifestyle, and environmental factors, precision medicine offers promising potential in treating cancer by moving away from a one-size-fits-all approach.
Individuals with a family history of certain cancers are at higher risk of inheriting the condition, and precision oncology enables them to undergo genetic testing to assess their risk. Early cancer screening facilitates early detection, leading to improved treatment outcomes. Notably, several precision cancer centers like MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Mayo Clinic Cancer Center in the US provide advanced technologies and treatments tailored for patients with rare or challenging cancers. Clinical trials of oncology precision medicines have demonstrated high efficacy, leading to increased participation of volunteers and consequently expanding the patient pool in such trials. This aids researchers in making better-informed decisions regarding evaluated drugs or technologies. With ongoing research and innovation in precision medicine, there is an anticipated significant increase in the adoption of targeted drugs, thereby driving growth in the oncology precision medicine market in the foreseeable future.
Key Market Segments
Type of Cancer Targeted
Bladder Cancer
Blood / Hematologic Cancer
Breast Cancer
Cervical Cancer
Gastrointestinal Cancer
Head and Neck Squamous Cell Cancer
Lung Cancer
Skin Cancer
Others
Route of Administration
Oral
Intravenous
Others
Type of Molecule
Small Molecules
Biologics
Drug Class
Kinase Inhibitors
Enzyme Inhibitors
Immune Checkpoint Inhibitors
Others
Leading Drug Developers
Merck
Pfizer
AstraZeneca
Johnson $ Johnson Innovative Medicine
Genentech
Key Geographical Regions
North America (US, Canada)
Europe (France, Germany, Italy, Spain and UK)
Asia (China, Japan, Korea and India)
Middle East and North Africa (UAE, Israel, Qatar and Rest of Middle East and North Africa)
Latin America (Brazil, Argentina, Chile and Rest of Latin America)
Research Coverage:
The report studies the oncology in precision market based on type of cancer targeted route of administration, type of molecule, drug class, key geographical regions.
The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.
The report forecasts the revenue of market segments with respect to five major regions
An overview of precision medicine, particularly in the field of oncology, is provided along with a comparison to traditional cancer medications. The process of developing oncology precision medicines is outlined, and the advantages they offer are discussed, highlighting their anticipated significance in shaping the future of personalized healthcare. Additionally, challenges associated with oncology precision medicine are addressed in this chapter.
The report provides an overview of oncology in precision medicine, including its evolution, types, and application areas. It also covers the benefits of these procedures compared to traditional beauty treatments and the side effects associated with them. The chapter also covers the key drivers of growth, new technologies, key issues and future prospects in this field.
Comprehensive analysis of the current landscape of oncology in precision medicine developers considering parameters such as establishment year, company size, headquarters, stage of development, approval body, approval region, drug designation, type of molecule, drug class, route of administration, dosage regimen, patient population and type of cancer targeted. Additionally, the chapter presents a detailed analysis of the current landscape of discovery and preclinical stage oncology precision medicines, based on several relevant parameters, such as stage of development, type of molecule, drug class and type of cancer targeted.
In-depth profiles of companies offering precision medicine, focusing on company overviews, financial information (where available), portfolio, recent advancements, and informed future prospects.
An analysis of partnerships established in this sector since 2018, covering clinical trial agreement, commercialization agreement, drug development agreement, drug development and commercialization agreement, drug distribution agreement, drug licensing agreement, manufacturing agreement, merger / acquisition, process development and manufacturing agreement, research agreement, research and development agreement, service agreement, technology utilization agreement and others.
A thorough examination of completed or ongoing clinical trials in the field of oncology precision medicine is conducted, focusing on several key parameters including trial registration year, patient enrollment numbers, trial phase, status, target patient demographics, gender distribution, types of cancer targeted, sponsorship or collaboration types, study design characteristics, intervention models, and trial purposes. The analysis also identifies the most active sponsors or collaborators, comprising both industry and non-industry players based on their sponsorship of clinical trials. Additionally, emerging focus areas and geographical trends are explored within this clinical trial analysis.
A case study is presented on developers of precision oncology assay kits, offering a detailed analysis across several parameters including development stage (commercialized and under development), regulatory certification and compliance, regional availability, test type, sample type, biomarker detection principle, turnaround time, cancer type targeted, and end-user demographics. Furthermore, the chapter includes insights on various assay kit developers, along with an analysis based on parameters such as establishment year, company size, and headquarters location.
The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
Key Benefits of Buying this Report
The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the oncology precision medicine market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
Key Market Companies
AbbVie
Anticancer Bioscience
Astellas Pharma
Astrazeneca
Bayer
Blueprint Medicines
Bristol Myers Squibb
Eli Lilly
Erasca
Genentech
GlaxoSmithKline
Hutchmed
IDEAYA Biosciences
Jiangsu Hengrui Pharmaceuticals
Johnson & Johnson Innovative Medicine
Merck
Novartis
Pfizer
Repare Therapeutics
Roche
Seagen
SpringWorks Therapeutics
Takeda Pharmaceutical
VERAXA Biotech GmbH
VRise Therapeutics
Product Code: RA100476
TABLE OF CONTENTS
1. PREFACE
- 1.1. Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Market Segmentations
- 2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
- 3.1. Chapter Overview
- 3.2. Market Dynamics
- 3.2.1. Time Period
- 3.2.1.1. Historical Trends
- 3.2.1.2. Current and Forecasted Estimates
- 3.2.2. Currency Coverage
- 3.2.2.1. Overview of Major Currencies Affecting the Market
- 3.2.2.2. Impact of Currency Fluctuations on the Industry
- 3.2.3. Foreign Exchange Impact
- 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
- 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 3.2.4. Recession
- 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
- 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
- 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
- 3.2.5.2. Potential Impact of Inflation on the Market Evolution
- 3.2.1. Time Period
4. EXECUTIVE SUMMARY
5. INTRODUCTION
- 5.1. Chapter Overview
- 5.2. Precision Medicine
- 5.2.1. Evolution of Precision Medicine
- 5.3. Oncology Precision Medicine
- 5.3.1. Oncology Precision Medicine over Traditional Cancer Medicine
- 5.3.2. Steps Involved in Developing Oncology Precision Medicine
- 5.3.3. Advantages Associated with Oncology Precision Medicine
- 5.3.3.1. Benefits to the Patients
- 5.3.3.2. Benefits to the Healthcare Providers
- 5.3.3.3. Benefits to the Cancer Researchers
- 5.3.4. Challenges Associated with Oncology Precision Medicines
- 5.3.5. Future Perspectives
6. ONCOLOGY PRECISION MEDICINE: MARKET LANDSCAPE
- 6.1. Chapter Overview
- 6.2. Oncology Precision Medicine: Commercialized and Clinical Stage Drugs Market Landscape
- 6.2.1. Analysis by Stage of Development
- 6.2.2. Analysis by Approval Body
- 6.2.3. Analysis by Approval Region
- 6.2.4. Analysis by Drug Designation
- 6.2.5. Analysis by Type of Molecule
- 6.2.6. Analysis by Drug Class
- 6.2.7. Analysis by Route of Administration
- 6.2.8. Analysis by Dosage Regimen
- 6.2.9. Analysis by Patient Population
- 6.2.10. Analysis by Type of Cancer Targeted
- 6.2.11. Analysis by Stage of Development and Type of Cancer Targeted
- 6.3. Oncology Precision Medicine: Preclinical and Discovery Stage Drugs Market Landscape
- 6.3.1. Analysis by Stage of Development
- 6.3.2. Analysis by Type of Molecule
- 6.3.3. Analysis by Drug Class
- 6.3.4. Analysis by Type of Cancer Targeted
- 6.4. Oncology Precision Medicine: Developer Landscape
- 6.4.1. Analysis by Year of Establishment
- 6.4.2. Analysis by Company Size
- 6.4.3. Analysis by Location of Headquarters (Region)
- 6.4.4. Analysis by Location of Headquarters (Country)
- 6.4.5. Analysis by Company Size and Location of Headquarters (Region)
- 6.4.6. Most Active Players: Analysis by Number of Oncology Precision Medicines
7. DETAILED COMPANY PROFILES
- 7.1. Chapter Overview
- 7.2. AstraZeneca
- 7.2.1. Company Overview
- 7.2.2. Financial Information
- 7.2.3. Oncology Precision Medicine Portfolio
- 7.2.4. Recent Developments and Future Outlook
- 7.3. Genentech
- 7.3.1. Company Overview
- 7.3.2. Financial Information
- 7.3.3. Oncology Precision Medicine Portfolio
- 7.3.4. Recent Developments and Future Outlook
- 7.4. Jiangsu Hengrui Pharmaceuticals
- 7.4.1. Company Overview
- 7.4.2. Oncology Precision Medicine Portfolio
- 7.4.3. Recent Developments and Future Outlook
- 7.5. Johnson & Johnson Innovative Medicine
- 7.5.1. Company Overview
- 7.5.2. Financial Information
- 7.5.3. Oncology Precision Medicine Portfolio
- 7.5.4. Recent Developments and Future Outlook
- 7.6. Novartis
- 7.6.1. Company Overview
- 7.6.2. Financial Information
- 7.6.3. Oncology Precision Medicine Portfolio
- 7.6.4. Recent Developments and Future Outlook
- 7.7. Pfizer
- 7.7.1. Company Overview
- 7.7.2. Financial Information
- 7.7.3. Oncology Precision Medicine Portfolio
- 7.7.4. Recent Developments and Future Outlook
- 7.8. SpringWorks Therapeutics
- 7.8.1. Company Overview
- 7.8.2. Oncology Precision Medicine Portfolio
- 7.8.3. Recent Developments and Future Outlook
8. SHORT COMPANY PROFILES
- 8.1. Chapter Overview
- 8.2. AbbVie
- 8.3. Anticancer Bioscience
- 8.4. Astellas Pharma
- 8.5. Bayer
- 8.6. Blueprint Medicines
- 8.7. Bristol Myers Squibb
- 8.8. Eli Lilly
- 8.9. Erasca
- 8.10. GlaxoSmithKline
- 8.11. Hutchmed
- 8.12. IDEAYA Biosciences
- 8.13. Merck
- 8.14. Repare Therapeutics
- 8.15. Roche
- 8.16. Seagen
- 8.17. Takeda Pharmaceutical
- 8.18. VERAXA Biotech
- 8.19. VRise Therapeutics
9. PARTNERSHIPS AND COLLABORATIONS
- 9.1. Chapter Overview
- 9.2. Partnership Models
- 9.3. Oncology Precision Medicine: Partnerships and Collaborations
- 9.3.1. Analysis by Year of Partnership
- 9.3.2. Analysis by Type of Partnership
- 9.3.3. Analysis by Year and Type of Partnership
- 9.3.4. Analysis by Type of Partner
- 9.3.5. Analysis by Drug Involved
- 9.3.6. Analysis by Type of Cancer Targeted
- 9.3.7. Most Active Players: Analysis by Number of Partnerships
- 9.3.8. Analysis by Geography
- 9.3.8.1. Local and International Agreements
- 9.3.8.2. Intracontinental and Intercontinental Agreements
10. CLINICAL TRIAL ANALYSIS
- 10.1. Chapter Overview
- 10.2. Scope and Methodology
- 10.3. Oncology Precision Medicine: Clinical Trial Analysis
- 10.3.1. Analysis by Trial Registration Year
- 10.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
- 10.3.3. Analysis by Trial Phase
- 10.3.4. Analysis of Number of Patients Enrolled by Trial Phase
- 10.3.5. Analysis by Trial Registration Year and Trial Phase
- 10.3.6. Analysis by Trial Status
- 10.3.7. Analysis by Trial Registration Year and Trial Status
- 10.3.8. Analysis by Target Patient Population
- 10.3.9. Analysis by Patient Gender
- 10.3.10. Analysis by Type of Cancer Targeted
- 10.3.11. Analysis by Type of Sponsor / Collaborator
- 10.3.12. Analysis by Study Design
- 10.3.12.1. Analysis by Type of Trial Masking
- 10.3.12.2. Analysis by Type of Intervention Model
- 10.3.12.3. Analysis by Type of Intervention
- 10.3.12.4. Analysis by Trial Purpose
- 10.3.13. Most Active Sponsors / Collaborators: Analysis by Number of Clinical Trials
- 10.3.13.1. Analysis by Leading Industry Players
- 10.3.13.2. Analysis by Leading Non-Industry Players
- 10.3.14. Word Cloud Analysis: Emerging Focus Areas
- 10.3.15. Analysis by Geography
- 10.3.15.1. Analysis of Clinical Trials by Geography
- 10.3.15.2. Analysis of Clinical Trials by Geography and Trial Status
- 10.3.15.3. Analysis of Patients Enrolled by Geography and Trial Status
11. CASE STUDY: ONCOLOGY PRECISION MEDICINE ASSAY KITS
- 11.1. Chapter Overview
- 11.2. Oncology Precision Medicine: Assay Kits
- 11.2.1. Analysis by Stage of Development
- 11.2.2. Analysis by Regulatory Certification / Compliance
- 11.2.3. Analysis by Regional Availability
- 11.2.4. Analysis by Type of Test
- 11.2.5. Analysis by Type of Sample Used
- 11.2.6. Analysis by Principle of Biomarker Detection
- 11.2.7. Analysis by Turnaround Time
- 11.2.8. Analysis by Type of Cancer Targeted
- 11.2.9. Analysis by Turnaround Time and Type of Cancer Targeted
- 11.2.10. Analysis by End-user
- 11.2.11. Analysis by Regional Availability and End-user
- 11.2.12. Analysis by Type of Cancer Targeted and End-user
- 11.3. Oncology Precision Medicine Assay Kits: Developer Landscape
- 11.3.1. Analysis by Year of Establishment
- 11.3.2. Analysis by Company Size
- 11.3.3. Analysis by Location of Headquarters (Region)
- 11.3.4. Analysis by Location of Headquarters (Country)
- 11.3.5. Analysis by Company Size and Location of Headquarters (Region)
- 11.3.6. Analysis by Business Model
- 11.3.7. Most Active Players: Analysis by Number of Oncology Precision Medicine Assay Kits
12. CASE STUDY: TECHNOLOGIES USED IN PRECISION MEDICINE
- 12.1. Chapter Overview
- 12.2. Technologies Used in Precision Medicine
- 12.2.1. Next Generation Sequencing in Precision Medicine
- 12.2.2. Nanotechnology in Precision Medicine
- 12.2.3. Molecular Imaging Technologies in Precision Medicine
- 12.2.4. Omics Technologies in Precision Medicine
- 12.2.5. Artificial Intelligence (AI) in Precision Medicine
- 12.3. Conclusion
13. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
- 13.1. Chapter Overview
- 13.2. Market Drivers
- 13.3. Market Restraints
- 13.4. Market Opportunities
- 13.5. Market Challenges
- 13.6. Conclusion
14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET
- 14.1. Chapter Overview
- 14.2. Assumptions and Methodology
- 14.3. Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
- 14.4. Scenario Analysis
- 14.4.1 Conservative Scenario
- 14.4.2. Optimistic Scenario
- 14.5. Key Market Segmentations
15. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF CANCER TARGETED
- 15.1. Chapter Overview
- 15.2. Key Assumptions and Methodology
- 15.3. Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
- 15.3.1. Bladder Cancer: Forecasted Estimates (2023-2035)
- 15.3.2. Blood / Hematologic Cancer: Forecasted Estimates (2023-2035)
- 15.3.3. Breast Cancer: Forecasted Estimates (2023-2035)
- 15.3.4. Cervical Cancer: Forecasted Estimates (2023-2035)
- 15.3.5. Gastrointestinal Cancer: Forecasted Estimates (2023-2035)
- 15.3.6. Head and Neck Squamous Cell Cancer: Forecasted Estimates (2023-2035)
- 15.3.7. Lung Cancer: Forecasted Estimates (2023-2035)
- 15.3.8. Skin Cancer: Forecasted Estimates (2023-2035)
- 15.3.9. Other Cancers: Forecasted Estimates (2023-2035)
- 15.4. Data Triangulation and Validation
16. ONCOLOGY PRECISION MEDICINE MARKET, BY ROUTE OF ADMINISTRATION
- 16.1. Chapter Overview
- 16.2. Key Assumptions and Methodology
- 16.3. Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
- 16.3.1. Oral: Forecasted Estimates (2023-2035)
- 16.3.2. Intravenous: Forecasted Estimates (2023-2035)
- 16.3.3. Others: Forecasted Estimates (2023-2035)
- 16.4. Data Triangulation and Validation
17. ONCOLOGY PRECISION MEDICINE MARKET, BY TYPE OF MOLECULE
- 17.1. Chapter Overview
- 17.2. Key Assumptions and Methodology
- 17.3. Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
- 17.3.1. Small Molecules: Forecasted Estimates (2023-2035)
- 17.3.2. Biologics: Forecasted Estimates (2023-2035)
- 17.4. Data Triangulation and Validation
18. ONCOLOGY PRECISION MEDICINE MARKET, BY DRUG CLASS
- 18.1. Chapter Overview
- 18.2. Key Assumptions and Methodology
- 18.3. Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
- 18.3.1. Kinase Inhibitors: Forecasted Estimates (2023-2035)
- 18.3.2. Enzyme Inhibitors: Forecasted Estimates (2023-2035)
- 18.3.3. Immune Checkpoint Inhibitors: Forecasted Estimates (2023-2035)
- 18.3.4. Others: Forecasted Estimates (2023-2035)
- 18.4. Data Triangulation and Validation
19. ONCOLOGY PRECISION MEDICINE MARKET, BY KEY GEOGRAPHICAL REGIONS
- 19.1. Chapter Overview
- 19.2. Key Assumptions and Methodology
- 19.3. Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035
- 19.3.1. North America: Forecasted Estimates (2023-2035)
- 19.3.1.1. US: Forecasted Estimates (2023-2035)
- 19.3.1.2. Canada: Forecasted Estimates (2023-2035)
- 19.3.2. Europe: Forecasted Estimates (2023-2035)
- 19.3.2.1. France: Forecasted Estimates (2023-2035)
- 19.3.2.2. Germany: Forecasted Estimates (2023-2035)
- 19.3.2.3. Italy: Forecasted Estimates (2023-2035)
- 19.3.2.4. Spain: Forecasted Estimates (2023-2035)
- 19.3.2.5. UK: Forecasted Estimates (2023-2035)
- 19.3.3. Asia: Forecasted Estimates (2023-2035)
- 19.3.3.1. China: Forecasted Estimates (2023-2035)
- 19.3.3.2. Japan: Forecasted Estimates (2023-2035)
- 19.3.3.3. Korea: Forecasted Estimates (2023-2035)
- 19.3.3.4. India: Forecasted Estimates (2023-2035)
- 19.3.4. Middle East and North Africa: Forecasted Estimates (2023-2035)
- 19.3.4.1. UAE: Forecasted Estimates (2023-2035)
- 19.3.4.2. Israel: Forecasted Estimates (2023-2035)
- 19.3.4.3. Qatar: Forecasted Estimates (2023-2035)
- 19.3.4.4. Rest of Middle east and North Africa: Forecasted Estimates (2023-2035)
- 19.3.5. Latin America: Forecasted Estimates (2023-2035)
- 19.3.5.1. Brazil: Forecasted Estimates (2023-2035)
- 19.3.5.2. Argentina: Forecasted Estimates (2023-2035)
- 19.3.5.3. Chile: Forecasted Estimates (2023-2035)
- 19.3.5.4. Rest of Latin America: Forecasted Estimates (2023-2035)
- 19.3.1. North America: Forecasted Estimates (2023-2035)
- 19.4. Data Triangulation and Validation
20. ONCOLOGY PRECISION MEDICINE MARKET, SALES FORECAST OF DRUGS
- 20.1. Chapter Overview
- 20.2. Key Assumptions and Methodology
- 20.3. Blockbuster Commercialzied Oncology Precision Medicine Market: Sales Forecast
- 20.3.1. ADCETRIS® Sales Forecast
- 20.3.2. Alecensa® Sales Forecast
- 20.3.3. ALUNBRIG® Sales Forecast
- 20.3.4. Avastin® Sales Forecast
- 20.3.5. Ayvakit® Sales Forecast
- 20.3.6. Braftovi®+ Mektovi® Sales Forecast
- 20.3.7. BRUKINSA® Sales Forecast
- 20.3.8. CALQUENCE® Sales Forecast
- 20.3.9. DARZALEX® Sales Forecast
- 20.3.10. Elunate® Sales Forecast
- 20.3.11. Empliciti® Sales Forecast
- 20.3.12. Enhertu® Sales Forecast
- 20.3.13. IBRANCE® Sales Forecast
- 20.3.14. ICLUSIG® Sales Forecast
- 20.3.15. IMBRUVICA® Sales Forecast
- 20.3.16. IMFINZI® Sales Forecast
- 20.3.17. INLYTA® Sales Forecast
- 20.3.18. Keytruda® Sales Forecast
- 20.3.19. Kadcyla® Sales Forecast
- 20.3.20. LENVIMA® / KISPLYX® Sales Forecast
- 20.3.21. Lumakras® / Lumykras® Sales Forecast
- 20.3.22. Mekinist® Sales Forecast
- 20.3.23. NERLYNX® Sales Forecast
- 20.3.24. NINLARO® Sales Forecast
- 20.3.25. Opdivo® Sales Forecast
- 20.3.26. Padcev® Sales Forecast
- 20.3.27. Piqray® Sales Forecast
- 20.3.28. Sprycel® Sales Forecast
- 20.3.29. Tabrecta® Sales Forecast
- 20.3.30. Tagrisso® Sales Forecast
- 20.3.31. Tasigna® Sales Forecast
- 20.3.32. Tecentriq® Sales Forecast
- 20.3.33. VENCLEXTA® Sales Forecast
- 20.3.34. Verzenio® / Verzenios Sales Forecast
- 20.3.35. Xospata® Sales Forecast
- 20.3.36. Xtandi® Sales Forecast
- 20.3.37. ZEJULA® Sales Forecast
- 20.4. NDA-filed Oncology Precision Medicine Market: Sales Forecast
- 20.4.1. Apatinib / Rivoceranib Sales Forecast
- 20.4.2. Elunate® Sales Forecast
- 20.5. Phase III Oncology Precision Medicine Market: Sales Forecast
- 20.5.1. Darovasertib / IDE196 Sales Forecast
- 20.5.1.1. Darovasertib / IDE196 Regional Sales Forecast
- 20.5.2. Elenestinib / BLU-263 Sales Forecast
- 20.5.2.1. Elenestinib / BLU-263 Regional Sales Forecast
- 20.5.3. Elunate® Sales Forecast
- 20.5.3.1. Elunate® Sales Forecast by Type of Cancer Targeted
- 20.5.3.2. Elunate® Regional Sales Forecast
- 20.5.4. ORPATHYS® Sales Forecast
- 20.5.4.1. ORPATHYS® Regional Sales Forecast
- 20.5.5. Pyrotinib Sales Forecast
- 20.5.5.1. Pyrotinib Sales Forecast by Type of Cancer Targeted
- 20.5.5.2. Pyrotinib Regional Sales Forecast
- 20.5.6. SYD985 / (Vic-) trastuzumab duocarmazine) Sales Forecast
- 20.5.6.1. SYD985 / (Vic-) trastuzumab duocarmazine) Regional Sales Forecast
- 20.5.7. ZOLINZA® Sales Forecast
- 20.5.7.1. ZOLINZA® Regional Sales Forecast
- 20.5.1. Darovasertib / IDE196 Sales Forecast
21. ONCOLOGY PRECISION MEDICINE MARKET, BY LEADING DRUG DEVELOPERS
- 21.1. Chapter Overview
- 21.2. Key Assumptions and Methodology
- 21.3. Oncology Precision Medicine Market: Distribution by Leading Drug Developers
- 21.4. Data Triangulation and Validattion
22. CONCLUSION
23. EXECUTIVE INSIGHTS
- 23.1. Chapter Overview
- 23.2. Allarity Therapeutics
- 23.2.1. Company Snapshot
- 23.2.2. Interview Transcrip
- 23.3. Elephas
- 23.3.1. Company Snapshot
- 23.3.2. Interview Transcript
24. APPENDIX 1: TABULATED DATA
25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Product Code: RA100476
List of Tables
- Table 6.1 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Developer, Brand, Stage of Development, Approval Body and Approval Region
- Table 6.2 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Drug Designation
- Table 6.3 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Type of Molecule, Drug Class, Route of Administration, Dosage Regimen and Patient Population
- Table 6.4 Commercialized and Clinical Stage Oncology Precision Medicine: Information on Type of Cancer Targeted
- Table 6.5 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Developer and Stage of Development
- Table 6.6 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Type of Molecule and Drug Class
- Table 6.7 Preclinical and Discovery Stage Oncology Precision Medicine: Information on Type of Cancer Targeted
- Table 6.8 Oncology Precision Medicine: List of Developers
- Table 7.1 Oncology Precision Medicine: List of Companies Profiled
- Table 7.2 AstraZeneca: Company Snapshot
- Table 7.3 AstraZeneca: Oncology Precision Medicine Portfolio
- Table 7.4 AstraZeneca: Recent Developments and Future Outlook
- Table 7.5 Genentech: Company Snapshot
- Table 7.6 Genentech: Oncology Precision Medicine Portfolio
- Table 7.7 Jiangsu Hengrui Pharmaceuticals: Company Snapshot
- Table 7.8 Jiangsu Hengrui Pharmaceuticals: Oncology Precision Medicine Portfolio
- Table 7.9 Johnson & Johnson Innovative Medicine: Company Snapshot
- Table 7.10 Johnson & Johnson Innovative Medicine: Oncology Precision Medicine Portfolio
- Table 7.11 Johnson & Johnson Innovative Medicine: Recent Developments and Future Outlook
- Table 7.12 Novartis: Company Snapshot
- Table 7.13 Novartis: Oncology Precision Medicine Portfolio
- Table 7.14 Novartis: Recent Developments and Future Outlook
- Table 7.15 Pfizer: Company Snapshot
- Table 7.16 Pfizer: Oncology Precision Medicine Portfolio
- Table 7.17 Pfizer: Recent Developments and Future Outlook
- Table 7.18 SpringWorks Therapeutics: Company Snapshot
- Table 7.19 SpringWorks Therapeutics: Oncology Precision Medicine Portfolio
- Table 7.20 SpringWorks Therapeutics: Recent Developments and Future Outlook
- Table 8.1 Oncology Precision Medicine: List of Companies Profiled
- Table 8.2 Company Profile: AbbVie
- Table 8.3 Company Profile: Anticancer Biosciences
- Table 8.4 Company Profile: Astellas Pharma
- Table 8.5 Company Profile: Bayer
- Table 8.6 Company Profile: Blueprint Medicines
- Table 8.7 Company Profile: Bristol Myers Squibb
- Table 8.8 Company Profile: Eli Lilly
- Table 8.9 Company Profile: Erasca
- Table 8.10 Company Profile: GlaxoSmithKline
- Table 8.11 Company Profile: Hutchmed
- Table 8.12 Company Profile: IDEAYA Biosciences
- Table 8.13 Company Profile: Merck
- Table 8.14 Company Profile: Repare Therapeutics
- Table 8.15 Company Profile: Roche
- Table 8.16 Company Profile: Seagen
- Table 8.17 Company Profile: Takeda Pharmaceutical
- Table 8.18 Company Profile: VERAXA Biotech GmbH
- Table 8.19 Company Profile: VRise Therapeutics
- Table 9.1 Oncology Precision Medicine: List of Partnerships and Collaborations, 2018-2023
- Table 9.2 Partnerships and Collaborations: Information on Drug Involved and Type of Cancer Targeted
- Table 9.3 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
- Table 11.1 Oncology Precision Medicine Assay Kits: Information on Developer, Stage of Development, Regulatory Certification / Compliance and Regional Availability
- Table 11.2 Oncology Precision Medicine Assay Kits: Information on Type of Test, Type of Sample, Principle of Biomarker Detection and Turn-around Time
- Table 11.3 Oncology Precision Medicine Assay Kits: Information on Type of Cancer Targeted
- Table 11.4 Oncology Precision Medicine Assay Kits: Information on End-user
- Table 11.5 List of Oncology Precision Medicine Assay Kit Developers
- Table 21.1 List of Leading Oncology Precision Medicine Developers
- Table 23.1 Allarity Therapeutics: Company Snapshot
- Table 23.2 Elephas: Company Snapshot
- Table 24.1 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development
- Table 24.2 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Body
- Table 24.3 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Region
- Table 24.4 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Designation
- Table 24.5 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Molecule
- Table 24.6 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Class
- Table 24.7 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Route of Administration
- Table 24.8 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Dosage Regimen
- Table 24.9 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Patient Population
- Table 24.10 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
- Table 24.11 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development and Type of Cancer Targeted
- Table 24.12 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Stage of Development
- Table 24.13 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Molecule
- Table 24.14 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Drug Class
- Table 24.15 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
- Table 24.16 Oncology Precision Medicine: Distribution of Drug Developers by Year of Establishment
- Table 24.17 Oncology Precision Medicine: Distribution of Drug Developers by Company Size
- Table 24.18 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Region)
- Table 24.19 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Country)
- Table 24.20 Oncology Precision Medicine: Distribution of Drug Developers by Company Size and Location of Headquarters (Region)
- Table 24.21 Most Active Developers: Distribution by Number of Oncology Precision Medicines
- Table 24.22 AstraZeneca: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
- Table 24.23 Roche (Parent Company of Genentech): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
- Table 24.24 Johnson & Johnson (Parent Company of Johnson & Johnson Innovative Medicine): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
- Table 24.25 Novartis: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
- Table 24.26 Pfizer: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
- Table 24.27 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2023
- Table 24.28 Partnerships and Collaborations: Distribution by Type of Partnership
- Table 24.29 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2018-2023
- Table 24.30 Partnerships and Collaborations: Distribution by Type of Partner
- Table 24.31 Partnerships and Collaborations: Distribution by Drug Involved
- Table 24.32 Partnerships and Collaborations: Distribution by Type of Cancer Targeted
- Table 24.33 Most Active Players: Distribution by Number of Partnerships
- Table 24.34 Partnership and Collaborations: Local and International Agreements
- Table 24.35 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
- Table 24.36 Clinical Trial Analysis: Cumulative Year-wise Trend, 2018-2023
- Table 24.37 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2018-2023
- Table 24.38 Clinical Trial Analysis: Distribution by Trial Phase
- Table 24.39 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
- Table 24.40 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2018-2023
- Table 24.41 Clinical Trial Analysis: Distribution by Trial Status
- Table 24.42 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2018-2023
- Table 24.43 Clinical Trial Analysis: Distribution by Target Patient Population
- Table 24.44 Clinical Trial Analysis: Distribution by Patient Gender
- Table 24.45 Clinical Trial Analysis: Distribution by Type of Cancer Targeted
- Table 24.46 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
- Table 24.47 Clinical Trial Analysis: Distribution by Type of Trial Masking
- Table 24.48 Clinical Trial Analysis: Distribution by Type of Intervention Model
- Table 24.49 Clinical Trial Analysis: Distribution by Type of Intervention
- Table 24.50 Clinical Trial Analysis: Distribution by Trial Purpose
- Table 24.51 Leading Industry Players: Distribution by Number of Clinical Trials
- Table 24.52 Leading Non-Industry Players: Distribution by Number of Clinical Trials
- Table 24.53 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
- Table 24.54 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
- Table 24.55 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
- Table 24.56 Oncology Precision Medicine Assay Kits: Distribution by Stage of Development
- Table 24.57 Oncology Precision Medicine Assay Kits: Distribution by Regulatory Certification / Compliance
- Table 24.58 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability
- Table 24.59 Oncology Precision Medicine Assay Kits: Distribution by Type of Test
- Table 24.60 Oncology Precision Medicine Assay Kits: Distribution by Type of Sample Used
- Table 24.61 Oncology Precision Medicine Assay Kits: Distribution by Principle of Biomarker Detection
- Table 24.62 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time
- Table 24.63 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted
- Table 24.64 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time and Type of Cancer Targeted
- Table 24.65 Oncology Precision Medicine Assay Kits: Distribution by End-user
- Table 24.66 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability and End-user
- Table 24.67 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted and End-user
- Table 24.68 Oncology Precision Medicine Assay Kit Developers: Distribution by Year of Establishment
- Table 24.69 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size
- Table 24.70 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Region)
- Table 24.71 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Country)
- Table 24.72 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size and Location of Headquarters (Region)
- Table 24.73 Oncology Precision Medicine Assay Kit Developers: Distribution by Business Model
- Table 24.74 Most Active Developers: Distribution by Number of Oncology Precision Medicine Assay Kits Developed
- Table 24.75 Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
- Table 24.76 Global Oncology Precision Medicine Market, 2023-2035: Conservative Scenario (USD Billion)
- Table 24.77 Global Oncology Precision Medicine Market, 2023-2035: Optimistic Scenario (USD Billion)
- Table 24.78 Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
- Table 24.79 Oncology Precision Medicine Market for Bladder Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.80 Oncology Precision Medicine Market for Blood / Hematologic Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.81 Oncology Precision Medicine Market for Breast Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.82 Oncology Precision Medicine Market for Cervical Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.83 Oncology Precision Medicine Market for Gastrointestinal Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.84 Oncology Precision Medicine Market for Head and Neck Squamous Cell Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.85 Oncology Precision Medicine Market for Lung Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.86 Oncology Precision Medicine Market for Skin Cancer, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.87 Oncology Precision Medicine Market for Other Cancers, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.88 Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
- Table 24.89 Oncology Precision Medicine Market for Oral, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.90 Oncology Precision Medicine Market for Intravenous, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.91 Oncology Precision Medicine Market for Others, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.92 Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
- Table 24.93 Oncology Precision Medicine Market for Small Molecules, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.94 Oncology Precision Medicine Market for Biologics, Conservative, Base and Optimistic Scenarios, 2023-2035, (USD Billion)
- Table 24.95 Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
- Table 24.96 Oncology Precision Medicine Market for Kinase Inhibitors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.97 Oncology Precision Medicine Market for Enzyme Inhibitors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.98 Oncology Precision Medicine Market for Immune Checkpoint Inhibitors, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.99 Oncology Precision Medicine Market for Others, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.100 Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035
- Table 24.101 Oncology Precision Medicine Market in North America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.102 Oncology Precision Medicine Market in the US, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.103 Oncology Precision Medicine Market in Canada, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.104 Oncology Precision Medicine Market in Europe, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.105 Oncology Precision Medicine Market in France, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.106 Oncology Precision Medicine Market in Germany, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.107 Oncology Precision Medicine Market in Italy, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.108 Oncology Precision Medicine Market in Spain, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.109 Oncology Precision Medicine Market in UK, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.110 Oncology Precision Medicine Market in Asia, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.111 Oncology Precision Medicine Market in China, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.112 Oncology Precision Medicine Market in Japan, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.113 Oncology Precision Medicine Market in Korea, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.114 Oncology Precision Medicine Market in India, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.115 Oncology Precision Medicine Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.116 Oncology Precision Medicine Market in UAE, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.117 Oncology Precision Medicine Market in Israel, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.118 Oncology Precision Medicine Market in Qatar, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.119 Oncology Precision Medicine Market in Rest of Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.120 Oncology Precision Medicine Market in Latin America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.121 Oncology Precision Medicine Market in Brazil, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.122 Oncology Precision Medicine Market in Argentina, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.123 Oncology Precision Medicine Market in Chile, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.124 Oncology Precision Medicine Market in Rest of Latin America, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.125 Blockbuster Commercialized Oncology Precision Medicine Market: ADCETRIS® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.126 Blockbuster Commercialized Oncology Precision Medicine Market: Alecensa® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.127 Blockbuster Commercialized Oncology Precision Medicine Market: ALUNBRIG® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.128 Blockbuster Commercialized Oncology Precision Medicine Market: Avastin® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.129 Blockbuster Commercialized Oncology Precision Medicine Market: Ayvakit® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.130 Blockbuster Commercialized Oncology Precision Medicine Market: Braftovi®+ Mektovi® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.131 Blockbuster Commercialized Oncology Precision Medicine Market: BRUKINSA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.132 Blockbuster Commercialized Oncology Precision Medicine Market: CALQUENCE® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.133 Blockbuster Commercialized Oncology Precision Medicine Market: DARZALEX® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.134 Blockbuster Commercialized Oncology Precision Medicine Market: Elunate® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.135 Blockbuster Commercialized Oncology Precision Medicine Market: Empliciti® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.136 Blockbuster Commercialized Oncology Precision Medicine Market: Enhertu® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.137 Blockbuster Commercialized Oncology Precision Medicine Market: IBRANCE® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.138 Blockbuster Commercialized Oncology Precision Medicine Market: ICLUSIG® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.139 Blockbuster Commercialized Oncology Precision Medicine Market: IMBRUVICA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.140 Blockbuster Commercialized Oncology Precision Medicine Market: IMFINZI® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.141 Blockbuster Commercialized Oncology Precision Medicine Market: INLYTA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.142 Blockbuster Commercialized Oncology Precision Medicine Market: Keytruda® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.143 Blockbuster Commercialized Oncology Precision Medicine Market: Kadcyla® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.144 Blockbuster Commercialized Oncology Precision Medicine Market: LENVIMA® / KISPLYX® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.145 Blockbuster Commercialized Oncology Precision Medicine Market: Lumakras® / Lumykras® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.146 Blockbuster Commercialized Oncology Precision Medicine Market: Mekinist® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.147 Blockbuster Commercialized Oncology Precision Medicine Market: NERLYNX® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.148 Blockbuster Commercialized Oncology Precision Medicine Market: NINLARO® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.149 Blockbuster Commercialized Oncology Precision Medicine Market: Opdivo® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.150 Blockbuster Commercialized Oncology Precision Medicine Market: Padcev® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.151 Blockbuster Commercialized Oncology Precision Medicine Market: Piqray® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.152 Blockbuster Commercialized Oncology Precision Medicine Market: Sprycel® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.153 Blockbuster Commercialized Oncology Precision Medicine Market: Tabrecta® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.154 Blockbuster Commercialized Oncology Precision Medicine Market: Tagrisso® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.155 Blockbuster Commercialized Oncology Precision Medicine Market: Tasigna® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.156 Blockbuster Commercialized Oncology Precision Medicine Market: Tecentriq® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.157 Blockbuster Commercialized Oncology Precision Medicine Market: VENCLEXTA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.158 Blockbuster Commercialized Oncology Precision Medicine Market: Verzenio® / Verzenios Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.159 Blockbuster Commercialized Oncology Precision Medicine Market: Xospata® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.160 Blockbuster Commercialized Oncology Precision Medicine Market: XTANDI® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.161 Blockbuster Commercialized Oncology Precision Medicine Market: ZEJULA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
- Table 24.162 NDA-filed Oncology Precision Medicine Market: Apatinib / Rivoceranib Sales Forecast, Conservative, Base and Optimistic Scenarios, 2024-2035 (USD Billion)
- Table 24.163 NDA-filed Oncology Precision Medicine Market: Elunate® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
- Table 24.164 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2035 (USD Billion)
- Table 24.165 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2035 (USD Billion)
- Table 24.166 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2035 (USD Billion)
- Table 24.167 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2030-2035 (USD Billion)
- Table 24.168 Phase III Oncology Precision Medicine Market: Elunate® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
- Table 24.169 Phase III Oncology Precision Medicine Market: Elunate® Sales Forecast by Type of Cancer Targeted, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
- Table 24.170 Phase III Oncology Precision Medicine Market: Elunate® Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
- Table 24.171 Phase III Oncology Precision Medicine Market: ORPATHYS® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2028-2035 (USD Billion)
- Table 24.172 Phase III Oncology Precision Medicine Market: ORPATHYS® Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2028-2035 (USD Billion)
- Table 24.173 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
- Table 24.174 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast by Type of Cancer Targeted, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
- Table 24.175 Phase III Oncology Precision Medicine Market: Pyrotinib Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
- Table 24.176 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
- Table 24.177 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-) trastuzumab duocarmazine) Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
- Table 24.178 Phase III Oncology Precision Medicine Market: ZOLINZA® Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
- Table 24.179 Phase III Oncology Precision Medicine Market: ZOLINZA® Regional Sales Forecast, Conservative, Base and Optimistic Scenarios, 2025-2035 (USD Billion)
- Table 24.180 Oncology Precision Medicine Market: Distribution by Leading Drug Developers (based on sales of oncology precision medicines in the year 2022 (USD Billion))
List of Figures
- Figure 2.1 Research Methodology: Research Assumptions
- Figure 2.2 Research Methodology: Project Methodology
- Figure 2.3 Research Methodology: Forecast Methodology
- Figure 2.4 Research Methodology: Robust Quality Control
- Figure 2.5 Research Methodology: Key Market Segmentations
- Figure 4.1 Executive Summary: Market Landscape
- Figure 4.2 Executive Summary: Partnerships and Collaborations
- Figure 4.3 Executive Summary: Clinical Trial Analysis
- Figure 4.4 Executive Summary: Market Forecast and Opportunity Analysis
- Figure 5.1 Evolution of Precision Medicine
- Figure 5.2 Oncology Precision Medicine over Traditional Cancer Medicine
- Figure 5.3 Steps Involved in Developing Oncology Precision Medicines
- Figure 5.4 Challenges Associated with Oncology Precision Medicines
- Figure 6.1 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development
- Figure 6.2 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Body
- Figure 6.3 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Approval Region
- Figure 6.4 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Designation
- Figure 6.5 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Molecule
- Figure 6.6 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Drug Class
- Figure 6.7 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Route of Administration
- Figure 6.8 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Dosage Regimen
- Figure 6.9 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Patient Population
- Figure 6.10 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
- Figure 6.11 Commercialized and Clinical Stage Oncology Precision Medicine: Distribution by Stage of Development and Type of Cancer Targeted
- Figure 6.12 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Stage of Development
- Figure 6.13 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Molecule
- Figure 6.14 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Drug Class
- Figure 6.15 Preclinical and Discovery Stage Oncology Precision Medicine: Distribution by Type of Cancer Targeted
- Figure 6.16 Oncology Precision Medicine: Distribution of Drug Developers by Year of Establishment
- Figure 6.17 Oncology Precision Medicine: Distribution of Drug Developers by Company Size
- Figure 6.18 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Region)
- Figure 6.19 Oncology Precision Medicine: Distribution of Drug Developers by Location of Headquarters (Country)
- Figure 6.20 Oncology Precision Medicine: Distribution of Drug Developers by Company Size and Location of Headquarters (Region)
- Figure 6.21 Most Active Developers: Distribution by Number of Oncology Precision Medicines
- Figure 7.1 AstraZeneca: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
- Figure 7.2 Roche (Parent Company of Genentech): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
- Figure 7.3 Johnson & Johnson (Parent Company of Johnson & Johnson Innovative Medicine): Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
- Figure 7.4 Novartis: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
- Figure 7.5 Pfizer: Annual Revenues, FY 2018-H1 FY 2023 (USD Billion)
- Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2018-2023
- Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
- Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2018-2023
- Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
- Figure 9.5 Partnerships and Collaborations: Distribution by Drug Involved
- Figure 9.6 Partnerships and Collaborations: Distribution by Type of Cancer Targeted
- Figure 9.7 Most Active Players: Distribution by Number of Partnerships
- Figure 9.8 Partnership and Collaborations: Local and International Agreements
- Figure 9.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
- Figure 10.1 Clinical Trial Analysis: Cumulative Year-wise Trend, 2018-2023
- Figure 10.2 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2018-2023
- Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase
- Figure 10.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
- Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, 2018-2023
- Figure 10.6 Clinical Trial Analysis: Distribution by Trial Status
- Figure 10.7 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, 2018-2023
- Figure 10.8 Clinical Trial Analysis: Distribution by Target Patient Population
- Figure 10.9 Clinical Trial Analysis: Distribution by Patient Gender
- Figure 10.10 Clinical Trial Analysis: Distribution by Type of Cancer Targeted
- Figure 10.11 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
- Figure 10.12 Clinical Trial Analysis: Distribution by Type of Trial Masking
- Figure 10.13 Clinical Trial Analysis: Distribution by Type of Intervention Model
- Figure 10.14 Clinical Trial Analysis: Distribution by Type of Intervention
- Figure 10.15 Clinical Trial Analysis: Distribution by Trial Purpose
- Figure 10.16 Leading Industry Players: Distribution by Number of Clinical Trials
- Figure 10.17 Leading Non-Industry Players: Distribution by Number of Clinical Trials
- Figure 10.18 Word Cloud Analysis: Emerging Focus Areas
- Figure 10.19 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
- Figure 10.20 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
- Figure 10.21 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
- Figure 11.1 Oncology Precision Medicine Assay Kits: Distribution by Stage of Development
- Figure 11.2 Oncology Precision Medicine Assay Kits: Distribution by Regulatory Certification / Compliance
- Figure 11.3 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability
- Figure 11.4 Oncology Precision Medicine Assay Kits: Distribution by Type of Test
- Figure 11.5 Oncology Precision Medicine Assay Kits: Distribution by Type of Sample Used
- Figure 11.6 Oncology Precision Medicine Assay Kits: Distribution by Principle of Biomarker Detection
- Figure 11.7 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time
- Figure 11.8 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted
- Figure 11.9 Oncology Precision Medicine Assay Kits: Distribution by Turnaround Time and Type of Cancer Targeted
- Figure 11.10 Oncology Precision Medicine Assay Kits: Distribution by End-user
- Figure 11.11 Oncology Precision Medicine Assay Kits: Distribution by Regional Availability and End-user
- Figure 11.12 Oncology Precision Medicine Assay Kits: Distribution by Type of Cancer Targeted and End-user
- Figure 11.13 Oncology Precision Medicine Assay Kit Developers: Distribution by Year of Establishment
- Figure 11.14 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size
- Figure 11.15 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Region)
- Figure 11.16 Oncology Precision Medicine Assay Kit Developers: Distribution by Location of Headquarters (Country)
- Figure 11.17 Oncology Precision Medicine Assay Kit Developers: Distribution by Company Size and Location of Headquarters (Region)
- Figure 11.18 Oncology Precision Medicine Assay Kit Developers: Distribution by Business Model
- Figure 11.19 Most Active Developers: Distribution by Number of Oncology Precision Medicine Assay Kits Developed
- Figure 12.1 Applications of NGS in Oncology Precision Medicine
- Figure 12.2 Applications of Nanotechnology in Oncology Precision Medicine
- Figure 12.3 Applications of Molecular Imaging Technologies in Oncology Precision Medicine
- Figure 12.4 Applications of Omics Technologies in Oncology Precision Medicine
- Figure 12.5 Applications of AI in Oncology Precision Medicine
- Figure 13.1 Oncology Precision Medicine: Market Drivers
- Figure 13.2 Oncology Precision Medicine: Market Restraints
- Figure 13.3 Oncology Precision Medicine: Market Opportunities
- Figure 13.4 Oncology Precision Medicine: Market Challenges
- Figure 14.1 Global Oncology Precision Medicine Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
- Figure 14.2 Global Oncology Precision Medicine Market, 2023-2035: Conservative Scenario (USD Billion)
- Figure 14.3 Global Oncology Precision Medicine Market, 2023-2035: Optimistic Scenario (USD Billion)
- Figure 15.1 Oncology Precision Medicine Market: Distribution by Type of Cancer Targeted, 2023, 2028 and 2035
- Figure 15.2 Oncology Precision Medicine Market for Bladder Cancer, 2023-2035 (USD Billion)
- Figure 15.3 Oncology Precision Medicine Market for Blood / Hematologic Cancer, 2023-2035 (USD Billion)
- Figure 15.4 Oncology Precision Medicine Market for Breast Cancer, 2023-2035 (USD Billion)
- Figure 15.5 Oncology Precision Medicine Market for Cervical Cancer, 2023-2035 (USD Billion)
- Figure 15.6 Oncology Precision Medicine Market for Gastrointestinal Cancer, 2023-2035 (USD Billion)
- Figure 15.7 Oncology Precision Medicine Market for Head and Neck Squamous Cancer, 2023-2035 (USD Billion)
- Figure 15.8 Oncology Precision Medicine Market for Lung Cancer, 2023-2035 (USD Billion)
- Figure 15.9 Oncology Precision Medicine Market for Skin Cancer, 2023-2035 (USD Billion)
- Figure 15.10 Oncology Precision Medicine Market for Other Cancers, 2023-2035 (USD Billion)
- Figure 16.1 Oncology Precision Medicine Market: Distribution by Route of Administration, 2023, 2028 and 2035
- Figure 16.2 Oncology Precision Medicine Market for Oral, 2023-2035 (USD Billion)
- Figure 16.3 Oncology Precision Medicine Market for Intravenous, 2023-2035 (USD Billion)
- Figure 16.4 Oncology Precision Medicine Market for Others, 2023-2035 (USD Billion)
- Figure 17.1 Oncology Precision Medicine Market: Distribution by Type of Molecule, 2023, 2028 and 2035
- Figure 17.2 Oncology Precision Medicine Market for Small Molecules, 2023-2035 (USD Billion)
- Figure 17.3 Oncology Precision Medicine Market for Biologics, 2023-2035, (USD Billion)
- Figure 18.1 Oncology Precision Medicine Market: Distribution by Drug Class, 2023, 2028 and 2035
- Figure 18.2 Oncology Precision Medicine Market for Kinase Inhibitors, 2023-2035 (USD Billion)
- Figure 18.3 Oncology Precision Medicine Market for Enzyme Inhibitors,2023-2035 (USD Billion)
- Figure 18.4 Oncology Precision Medicine Market for Immune Checkpoint Inhibitors, 2023-2035 (USD Billion)
- Figure 18.5 Oncology Precision Medicine Market for Others, 2023-2035 (USD Billion)
- Figure 19.1 Oncology Precision Medicine Market: Distribution by Key Geographical Regions, 2023, 2028 and 2035
- Figure 19.2 Oncology Precision Medicine Market in North America, 2023-2035 (USD Billion)
- Figure 19.3 Oncology Precision Medicine Market in the US, 2023-2035 (USD Billion)
- Figure 19.4 Oncology Precision Medicine Market in Canada, 2023-2035 (USD Billion)
- Figure 19.5 Oncology Precision Medicine Market in Europe, 2023-2035 (USD Billion)
- Figure 19.6 Oncology Precision Medicine Market in France, 2023-2035 (USD Billion)
- Figure 19.7 Oncology Precision Medicine Market in Germany, 2023-2035 (USD Billion)
- Figure 19.8 Oncology Precision Medicine Market in Italy, 2023-2035 (USD Billion)
- Figure 19.9 Oncology Precision Medicine Market in Spain, 2023-2035 (USD Billion)
- Figure 19.10 Oncology Precision Medicine Market in UK, 2023-2035 (USD Billion)
- Figure 19.11 Oncology Precision Medicine Market in Asia, 2023-2035 (USD Billion)
- Figure 19.12 Oncology Precision Medicine Market in China, 2023-2035 (USD Billion)
- Figure 19.13 Oncology Precision Medicine Market in Japan, 2023-2035 (USD Billion)
- Figure 19.14 Oncology Precision Medicine Market in Korea, 2023-2035 (USD Billion)
- Figure 19.15 Oncology Precision Medicine Market in India, 2023-2035 (USD Billion)
- Figure 19.16 Oncology Precision Medicine Market in Middle East and North Africa, 2023-2035 (USD Billion)
- Figure 19.17 Oncology Precision Medicine Market in UAE, 2023-2035 (USD Billion)
- Figure 19.18 Oncology Precision Medicine Market in Israel, 2023-2035 (USD Billion)
- Figure 19.19 Oncology Precision Medicine Market in Qatar, 2023-2035 (USD Billion)
- Figure 19.20 Oncology Precision Medicine Market in Rest of Middle East and North Africa, 2023-2035 (USD Billion)
- Figure 19.21 Oncology Precision Medicine Market in Latin America, 2023-2035 (USD Billion)
- Figure 19.22 Oncology Precision Medicine Market in Brazil, 2023-2035 (USD Billion)
- Figure 19.18 Oncology Precision Medicine Market in Israel, 2023-2035 (USD Billion)
- Figure 19.19 Oncology Precision Medicine Market in Chile, 2023-2035 (USD Billion)
- Figure 19.20 Oncology Precision Medicine Market in Rest of Latin America, 2023-2035 (USD Billion)
- Figure 20.1 Blockbuster Commercialized Oncology Precision Medicine Market: ADCETRISR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.2 Blockbuster Commercialized Oncology Precision Medicine Market: AlecensaR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.3 Blockbuster Commercialized Oncology Precision Medicine Market: ALUNBRIGR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.4 Blockbuster Commercialized Oncology Precision Medicine Market: AvastinR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.5 Blockbuster Commercialized Oncology Precision Medicine Market: AyvakitR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.6 Blockbuster Commercialized Oncology Precision Medicine Market: BraftoviR+ MektoviR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.7 Blockbuster Commercialized Oncology Precision Medicine Market: BRUKINSAR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.8 Blockbuster Commercialized Oncology Precision Medicine Market: CALQUENCER Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.9 Blockbuster Commercialized Oncology Precision Medicine Market: DARZALEXR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.10 Blockbuster Commercialized Oncology Precision Medicine Market: ElunateR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.11 Blockbuster Commercialized Oncology Precision Medicine Market: EmplicitiR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.12 Blockbuster Commercialized Oncology Precision Medicine Market: EnhertuR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.13 Blockbuster Commercialized Oncology Precision Medicine Market: IBRANCER Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.14 Blockbuster Commercialized Oncology Precision Medicine Market: ICLUSIGR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.15 Blockbuster Commercialized Oncology Precision Medicine Market: IMBRUVICAR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.16 Blockbuster Commercialized Oncology Precision Medicine Market: IMFINZIR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.17 Blockbuster Commercialized Oncology Precision Medicine Market: INLYTAR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.18 Blockbuster Commercialized Oncology Precision Medicine Market: KeytrudaR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.19 Blockbuster Commercialized Oncology Precision Medicine Market: KadcylaR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.20 Blockbuster Commercialized Oncology Precision Medicine Market: LENVIMAR / KISPLYXR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.21 Blockbuster Commercialized Oncology Precision Medicine Market: LumakrasR / LumykrasR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.22 Blockbuster Commercialized Oncology Precision Medicine Market: MekinistR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.23 Blockbuster Commercialized Oncology Precision Medicine Market: NERLYNXR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.24 Blockbuster Commercialized Oncology Precision Medicine Market: NINLAROR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.25 Blockbuster Commercialized Oncology Precision Medicine Market: OpdivoR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.26 Blockbuster Commercialized Oncology Precision Medicine Market: PadcevR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.27 Blockbuster Commercialized Oncology Precision Medicine Market: PiqrayR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.28 Blockbuster Commercialized Oncology Precision Medicine Market: SprycelR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.29 Blockbuster Commercialized Oncology Precision Medicine Market: TabrectaR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.30 Blockbuster Commercialized Oncology Precision Medicine Market: TagrissoR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.31 Blockbuster Commercialized Oncology Precision Medicine Market: TasignaR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.32 Blockbuster Commercialized Oncology Precision Medicine Market: TecentriqR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.33 Blockbuster Commercialized Oncology Precision Medicine Market: VENCLEXTAR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.34 Blockbuster Commercialized Oncology Precision Medicine Market: VerzenioR / Verzenios Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.35 Blockbuster Commercialized Oncology Precision Medicine Market: XospataR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.36 Blockbuster Commercialized Oncology Precision Medicine Market: XTANDIR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.37 Blockbuster Commercialized Oncology Precision Medicine Market: ZEJULAR Sales Forecast, 2023-2035 (USD Billion)
- Figure 20.38 NDA-filed Oncology Precision Medicine Market: Apatinib / Rivoceranib Sales Forecast, 2024-2035 (USD Billion)
- Figure 20.39 NDA-filed Oncology Precision Medicine Market: ElunateR Sales Forecast, 2025-2035 (USD Billion)
- Figure 20.40 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Sales Forecast, 2030-2035 (USD Billion)
- Figure 20.41 Phase III Oncology Precision Medicine Market: Darovasertib / IDE196 Regional Sales Forecast, 2030-2035 (USD Billion)
- Figure 20.42 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Sales Forecast, 2030-2035 (USD Billion)
- Figure 20.43 Phase III Oncology Precision Medicine Market: Elenestinib / BLU-263 Regional Sales Forecast, 2030-2035 (USD Billion)
- Figure 20.44 Phase III Oncology Precision Medicine Market: ElunateR Sales Forecast, 2025-2035 (USD Billion)
- Figure 20.45 Phase III Oncology Precision Medicine Market: ElunateR Sales Forecast by Type of Cancer Targeted, 2025-2035 (USD Billion)
- Figure 20.46 Phase III Oncology Precision Medicine Market: ElunateR Regional Sales Forecast, 2025-2035 (USD Billion)
- Figure 20.47 Phase III Oncology Precision Medicine Market: ORPATHYSR Sales Forecast, 2028-2035 (USD Billion)
- Figure 20.48 Phase III Oncology Precision Medicine Market: ORPATHYSR Regional Sales Forecast, 2028-2035 (USD Billion)
- Figure 20.49 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast, 2025-2035 (USD Billion)
- Figure 20.50 Phase III Oncology Precision Medicine Market: Pyrotinib Sales Forecast by Type of Cancer Targeted, 2025-2035 (USD Billion)
- Figure 20.51 Phase III Oncology Precision Medicine Market: Pyrotinib Regional Sales Forecast, 2025-2035 (USD Billion)
- Figure 20.52 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Sales Forecast, 2025-2035 (USD Billion)
- Figure 20.53 Phase III Oncology Precision Medicine Market: SYD985 / (Vic-)trastuzumab duocarmazine) Regional Sales Forecast, 2025-2035 (USD Billion)
- Figure 20.54 Phase III Oncology Precision Medicine Market: ZOLINZAR Sales Forecast, 2024-2035 (USD Billion)
- Figure 20.55 Phase III Oncology Precision Medicine Market: ZOLINZAR Regional Sales Forecast, 2024-2035 (USD Billion)
- Figure 21.1 Oncology Precision Medicine Market: Distribution by Leading Drug Developers (based on sales of oncology precision medicines in the year 2022 (USD Billion))
- Figure 22.1 Conclusion: Market Landscape
- Figure 22.2 Conclusion: Partnerships and Collaborations
- Figure 22.3 Conclusion: Clinical Trial Analysis
- Figure 22.4 Conclusion: Case Study Oncology Precision Medicine Assay Kits
- Figure 22.5 Conclusion: Market Forecast and Opportunity Analysis
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.